18:04 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Lilly drops BACE inhibitors for Alzheimer’s

Eli Lilly and Co. (NYSE:LLY) discontinued the combination arm evaluating anti-β-amyloid mAb LY3002813 plus BACE inhibitor LY3202626 in the Phase II TRAILBLAZER-ALZ trial to treat Alzheimer's disease. Spokesperson Nicole Herbert told BioCentury that Lilly has...
18:19 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Lilly, AZ stop Phase III Alzheimer's trials of BACE inhibitor

Eli Lilly and Co. (NYSE:LLY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued a pair of Phase III trials evaluating once-daily oral lanabecestat (AZD3293, LY3314814) to treat Alzheimer's disease after an IDMC analysis concluded that both trials...
11:29 , Jun 12, 2018 |  BC Extra  |  Clinical News

Lilly, AZ stop Phase III Alzheimer's trials of BACE inhibitor

Eli Lilly and Co. (NYSE:LLY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued a pair of Phase III trials evaluating once-daily oral lanabecestat (AZD3293, LY3314814) to treat Alzheimer's disease after an IDMC analysis concluded that both trials...
19:02 , May 31, 2018 |  BC Innovations  |  Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
18:23 , May 25, 2018 |  BC Week In Review  |  Clinical News

Janssen discontinues two Alzheimer's trials for BACE inhibitor

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said it is discontinuing two trials testing atabecestat (JNJ-54861911) to treat Alzheimer's disease after an evaluation showed the therapy led to elevated liver enzyme levels....
21:51 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Amgen, Novartis start Phase II to prevent AD

In August, Novartis AG (NYSE:NVS; SIX:NOVN), Amgen Inc. (NASDAQ:AMGN) and the Banner Alzheimer’s Institute (BAI) began the Phase II Alzheimer’s Prevention Initiative (API) Generation Study 2 to evaluate CNP520 to prevent Alzheimer’s disease. The double-blind,...
18:59 , Oct 27, 2017 |  BC Week In Review  |  Company News

Eisai exercises option for Biogen's anti-beta amyeloid mAb

Eisai Co. Ltd. (Tokyo:4523) exercised an option to co-develop and co-promote aducanumab (BIIB037) from Biogen Inc. (NASDAQ:BIIB). The industry has kept a close watch on the human recombinant anti- beta amyloid mAb after it became...
22:09 , Oct 23, 2017 |  BC Extra  |  Company News

Eisai exercises option for Biogen’s anti-beta amyloid mAb

Eisai Co. Ltd. (Tokyo:4523) exercised an option to co-develop and co-promote aducanumab (BIIB037) from Biogen Inc. (NASDAQ:BIIB). The industry has kept a close watch on the human recombinant anti- beta amyloid mAb after it became...
02:31 , Mar 4, 2017 |  BioCentury  |  Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...
01:09 , Feb 15, 2017 |  BC Extra  |  Clinical News

Merck stopping Phase III study of BACE inhibitor

Merck & Co. Inc. (NYSE:MRK) said it will halt the Phase II/III EPOCH study of verubecestat (MK-8931) to treat mild to moderate Alzheimer's disease based on findings of an external data monitoring committee (DMC), which...